StavroulakisKBisdasTTorselloGCombined directional atherectomy and drug-eluting balloon angioplasty for isolated popliteal artery lesions in patients with peripheral artery disease. J Endovasc Ther. 2015;22:847–852.
2.
CioppaAStabileETesorioT. Commentary: Never forget your old toys when you get new ones. J Endovasc Ther. 2015;22:853–854.
3.
TepeGLairdJSchneiderPDrug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
4.
WerkMAlbrechtTMeyerDPaclitaxel–coated balloons reduce restenosis after femoropopliteal angioplasty. Evidence from the randomized PACIFIER Trial. Circ Cardiovasc Interv. 2012;5:831–840.
5.
ScheinertDDudaSZellerTThe LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–19.
6.
ScheinertDSchulteKLZellerTPaclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21.
7.
TepeGZellerTSchnorrBHigh-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.
8.
MicariACioppaAVadalàGClinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331–838.
9.
TepeG. IN.PACT SFA trial and IN.PACT Global study: study design and clinical data overview. Paper presented at: VIVA 2014; November 4–9, 2014; Las Vegas, NV, USA.
10.
SchmidtA. Real world use of DCB in long femoropopliteal lesions—2 years results. Paper presented at: LINC 2014; January 28, 2014; Leipzig, Germany.
11.
ZellerTRastanAMacharzinaRDrug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Ther. 2014;21:359–368.
12.
FanelliFCannavaleAGazzettiMCalcium burden assessment and impact on drug-eluting balloons in peripheral artery disease. Cardiovasc Intervent Radiol. 2014;37:898–907.
13.
CioppaAStabileEPopusoiGCombined treatment of heavy calcified femoropopliteal lesions using directional atherectomy and a paclitaxel coated balloon: one year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–223.
14.
SchmidtA. Leipzig Rotarex plus DCB Registry. Paper presented at: LINC 2014; January 28, 2014; Leipzig, Germany.
15.
ZellerT. DEFINITIVE AR, a multinational pilot study evaluating the effectiveness of directional atherectomy + anti-restenotic therapy. Paper presented at: VIVA 2014; November 4, 2014; Las Vegas, NV, USA.
